# Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma

> **NCT00398515** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 25 (actual)

## Conditions studied

- Refractory Multiple Myeloma
- Stage II Multiple Myeloma
- Stage III Multiple Myeloma

## Interventions

- **DRUG:** lenalidomide
- **DRUG:** temsirolimus
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00398515
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2012-02
- **Final completion:** —
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2013-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00398515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00398515, "Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00398515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*